ovarian cancer awareness in the uk, page-8

Ok lets try and get this cleared up. The article champ2003 is referring to the following.

'The company said the UK market potential was more than 750,000 units potentially worth
more than $5 million.'

The company said
'HealthLinx Limiteds (ASX:HTX) UK distribution partner Intus Healthcare is targeting a large share of the potential 750,000 annual ovarian cancer diagnostic tests undertaken in the UK with the product launch of OvPlex on 25 February 2010.'

The company also said 'This will be the first large scale roll out of OvPlex and HealthLinx will receive a royalty of approximately $70 per test subject to exchange rates'

So either the article has left a 0 off the end and it should be 50 million or the company expects to sell about 75 thousand tests in the UK. But I suspect since they say large share of 750000 units that it would be the article has left a 0 off the end and it should be 50 million.

It would be good to clarify this with the company Monday exactly what is meant by 'large share'.
Anyway with the potential of UK, Europe, Asia and America and just under 126 million shares at 18 cents for a market cap of around 23 million this could be a real growth story of 2010.

Enjoy the ride, its going to be volitile.

Regards

MikePike